BFAM Member Spotlights

Meet the members of the Stanford Medicine Black Faculty Affinity Meetings (BFAM), a network created through OFDD's Community Support Initiative. BFAM is intended to provide networking and social engagement opportunities for Stanford Medicine faculty across all clinical lines and departments.

Eldrin Lewis, MD, MPH

Medicine/Cardiovascular Medicine

Chief, Cardiovascular Division

Research Interests
Quality of life in CV Disease, clinical trials of innovative therapies

Something you wouldn’t know just by looking at me.
I love jazz, especially classic female jazz vocalists

What are some of your favorite social activities?
Basketball, hiking, photography

Full Stanford Profile

Simon H. Stertzer, MD, Professor

eflewis1@stanford.edu

Bio

Dr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine. Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives. A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life. Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health. Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living. Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes. He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration. Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure. He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials.

Publications

Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. The New England journal of medicine Pfeffer, M. A., Claggett, B., Lewis, E. F., Granger, C. B., Kober, L., Maggioni, A. P., Mann, D. L., McMurray, J. J., Rouleau, J., Solomon, S. D., Steg, P. G., Berwanger, O., Cikes, M., De Pasquale, C. G., East, C., Fernandez, A., Jering, K., Landmesser, U., Mehran, R., Merkely, B., Vaghaiwalla Mody, F., Petrie, M. C., Petrov, I., Schou, M., Senni, M., Sim, D., van der Meer, P., Lefkowitz, M., Zhou, Y., Gong, J., Braunwald, E., PARADISE-MI Investigators and Committees, Pfeffer, M., Braunwald, E., Granger, C. B., Kober, L., Mann, D. L., Maggioni, A. P., McMurray, J. J., Rouleau, J. L., Solomon, S. D., Steg, P. G., Dargie, H., Foley, R., Francis, G. S., Komajda, M., Pocock, S., Lewis, E., Barkoudah, E., Brahimi, A., Correa-Gaviria, S., Cunningham, J., Finn, P., Hartley, H., Jering, K., McCausland, F. R., McGrath, M. M., Vaduganathan, M., Duong, C., Mercier, R., Roach, A., Saunders-Correa, B., Wivagg, A., Charytan, D., Joseph, J., Kaplan, A. P., Busse, P., Zuraw, B., Claggett, B., Fernandez, A., Barrionuevo, M., Albisu, J., Avaca, H., Brasca, D., Cartasegna, L., Casas, M., Costabel, J., de la Fuente, R., Duronto, E., Ferre Pacora, F., Guetta, J., Hominal, M., Hrabar, A., Luquez, H., Macin, S., Muntaner, J., Nani, S., Pizarro, R., Poy, C., Prado, A., Schiavi, L., Wenetz, L., Zapata, G., Zivano, D., De Pasquale, C., Amerena, J., Atherton, J., Lam, K., McKenzie, S., Roberts-Thomson, P., von Lewinski, D., Auer, J., Ebner, C., Hoppe, U., Mortl, D., Schober, A., Zaruba, M., Claeys, M., Cools, F., Gabriel, L., Janssens, S., Mullens, W., Van der Stighelen, H., Vanduynhoven, P., Berwanger, O., Arantes, F., Kormann, A., Maia, L., Manenti, E., Neuenschwander, F., Nicolau, J., Pimentel Filho, P., Precoma, D., Rassi, S., Rossi, P., Saraiva, J., Silva, R., Petrov, I., Atanasov, A., Dimitrov, C., Dimov, B., Gatzov, P., Jorgova Makedonska, J., Konteva, M., Markov, D., Mazhdrakov, G., Milanova, M., Panayotov, P., Raev, D., Stavreva, E., Stoyanov, M., Tisheva Gospodinova, S., Tokmakova, M., Tzekova, M., Tanguay, J., Gosselin, G., Mielniczuk, L., Moe, G., Robinson, S., Rodes-Cabau, J., Sia, Y., Welsh, R., Han, Y., Bai, F., Chen, J., Chen, H., Dong, Y., Fu, L., Gao, W., Gong, H., Huang, W., Li, Y., Li, X., Liu, S., Liu, F., Peng, D., Shen, A., Su, G., Sun, Y., Sun, J., Xu, B., Kong, X., Yao, Z., Yu, Z., Yuan, Z., Yuan, J., Zhou, Y., Cadena Bonfanti, A. J., Arana, C., Botero, R., Chavarriaga, J., Garcia, R., Gomez, E., Cikes, M., Gabor, M., Milicic, D., Trbusic, M., Widimsky, P., Belohlavek, J., Coufal, Z., Hromadka, M., Kala, P., Kettner, J., Motovska, Z., Podpera, I., Polasek, R., Schou, M., Due Vestergaard, L., Egstrup, K., Hollingdal, M., Koeber, L., Taskiran, M., Vraa, S., Vikman, S., Jaaskelainen, P., Nyman, K., Steg, G., Angoulvant, D., Barone-Rochette, G., Coste, P., Dubreuil, O., Elbaz, M., Henry, P., Mewton, N., Puymirat, E., Rosamel, Y., Landmesser, U., Bott, M., Brachmann, J., Cuneo, A., Dahl, J., Felix, S., Gutersohn, A., Haude, M., Horacek, T., Huegl, B., Jung, W., Kadel, C., Leschke, M., Lutz, M., Menck, N., Minden, H., Mittag, M., Nordbeck, P., Pfister, R., Pulz, J., Rassaf, T., Schwefer, M., Schwimmbeck, P., von Scheidt, W., Wienbergen, H., Winzer, E., Wolf, D., Yueksel, D., Zeh, W., Zeiher, A., Zeymer, U., Filippatos, G., Giamouzis, G., Karavidas, A., Milkas, A., Paraskevaidis, I., Patsilinakos, S., Tsioufis, K., Tziakas, D., Merkely, B., Andreka, P., Edes, I., Forster, T., Horvath, I., Kiss, R., Lupkovics, G., Noori, E., Tomcsanyi, J., Kerkar, P., Abdullakutty, J., Agarwal, D., Bhalani, N., Bhatia, T., Chanana, B., Chopada, M., Deshmukh, P., Hiremath, S., Karna, S., Mehta, A., Mittal, S., Premchand, R., Rathnavel, S., Ravikanth, A., Shah, U., Amir, O., Arbel, Y., Eisen, A., Halabi, M., Katz, A., Kinany, W., Zukerman, R., Senni, M., Barilla, F., Calabro, P., Camporotondo, R., Cannarile, P., D'Aiello, I., Ferrante, G., Fucili, A., Indolfi, C., Marenzi, G., Metra, M., Oliva, F., Pedone, C., Piovaccari, G., Prati, F., Sinagra, G., Taddei, F., Carrillo-Calvillo, J., Baleon, F., Bazzoni, A., de Los Rios, M., Leon, S., Rodriguez, J., Virgen, L., van der Meer, P., Al-Windy, N., De Nooijer, C., En Hartog, F., Dirksen, M., Elvan, A., Hamer, B., Jansen, A., Keijzers, M., Linssen, G., Magro, M., Manintveld, O., Nierop, P., Roemer, T., Schaap, J., Swart, H., Symersky, T., Troquay, R., van de Wal, R., van Heerebeek, L., Westendorp, I., Zoet, S., Gullestad, L., Al-Ani, R., Manhenke, C., Lema, J., Nunez, P., Rodriguez, A., Roldan, Y., Sanabria, E., Anonuevo, J., Abola, M., Sison, J., Tirador, L., Opolski, G., Blaszczak, P., Gil, R., Sobkowicz, B., Suckiel, M., Morais, J., Almeida, F., Azevedo, P., Brito, D., Ferreira, J., Lourenco, C., Marques, N., Moreira, J., Oliveira, L., Pereira, H., Pernencar, S., Cho, M., Jeong, M., Shim, W., Yoo, B., Vinereanu, D., Babes, K., Benedek, I., Chioncel, O., Ciobotaru, G., Dorobantu, M., Giuca, A., Iancu, A., Ionac, A., Militaru, C., Popescu, A., Rusu, R., Serban, L., Sinescu, C., Spiridon, M., Stanciulescu, G., Teodorescu, I., Teodoru, M., Todea, B., Tomescu, M., Barbarash, O., Agafina, A., Baranov, E., Berns, S., Boldueva, S., Kashtalap, V., Khaisheva, L., Khirmanov, V., Klein, G., Kobalava, Z., Kosmacheva, E., Kostenko, V., Lipchenko, A., Lomakin, N., Nosov, V., Petrov, A., Pevzner, D., Reznik, E., Ryabov, V., Scheglova, L., Shogenov, Z., Shvarts, Y., Timofeev, A., Yakovlev, A., Zykov, M., Sim Kheng Leng, D., D, S., Liew, M., Studencan, M., Blasko, P., Hudec, M., Jankajova, M., Slanina, M., Stevlik, J., Tomasovic, B., Ntsekhe, M., Corbett, C., Dawood, S., Gould, T., van Zyl, L., Nunez Villota, J., Bayon, J., Bueno, H., Crespo, M., Garcia, C., Garcia, E., Garcia, J., Gomez, J., Miro, V., Pascual, D., Pena, G., Reyes, A., Sionis, A., Christersson, C., Aladellie, L., Frick, M., Lonnberg, I., Mokhtari, A., Skoglund, K., Toernerud, M., Utter, F., Moccetti, T., Hunziker, L., Suter, T., Kobza, R., Maeder, M., Kao, H., Su, C. H., Chiang, C. Y., Tsao, H. M., Wen, M. S., Lo, P. H., Sung, S. H., Wu, Y. W., Kiatchoosakun, S., Ariyachaipanich, A., Kuanprasert, S., Sriratanasathavorn, C., Birhan Yilmaz, M., Akin, M., Badak, O., Cavusoglu, Y., Celik, O., Celik, A., Gecmen, C., Keles, T., Kutlu, M., Sahin, T., Turgut, O., Yigit, Z., Petrie, M., Zaman, A., Austin, D., Dixon, L., Glover, J., Hall, A., Jhund, P., Lee, K., Moriarty, A., O'Kane, P., Ryding, A., Squire, I., Trevelyan, J., Venugopal, V., East, C., Mehran, R., Mody, F., Ahmad, H., Alviar, C., Amidon, T., Ariani, M., Arora, V., Barman, N., Baron, S., Barringhaus, K., Bass, K., Bernstein, M., Bhagwat, R., Birchem, J., Blair, G., Blick, D., Cavender, M., Cebe, J., Chen, M., Cohn, J., Colfer, H., Dib, N., Duffy, B., Erickson, B., Fischer, S., Fung, G., Ghazi, F., Go, J., Graham, B., Gudipati, C., Guynes, R., Haddad, T., Hage, F., Hamzeh, I., Harris, B., Harrison, R., Hawa, Z., Heilman, K., Hinchman, D., Horwitz, P., Huth, M., Iteld, B., Jaffrani, N., Jain, A., Kang, G., Khant, R., Kono, A., Kozak, M., Kumar, V., Landers, D., Laney, P., Lombardo, D., Maheshwari, A., McGinty, J., McMillan, E., Mikdadi, G., Miller, G., Moustakakis, E., Nader, S., Nelson, W., O'Brien, T., Olson, C., Ooi, H., Prasanna, V., Prashad, R., Rees, A., Rennyson, S., Rogers, C., Schultz, J., Shah, R., Sharma, S., Singh, N., Sizemore, B., Soverow, J., Steuter, J., Suh, D., Tolerico, P., Tran, H., Treasure, C., Wallace, E., Wang, J., Wang, L., Wiseman, A., Zughaib, M. 2021; 385 (20): 1845-1855 More

Abstract

BACKGROUND: In patients with symptomatic heart failure, sacubitril-valsartan has been found to reduce the risk of hospitalization and death from cardiovascular causes more effectively than an angiotensin-converting-enzyme inhibitor. Trials comparing the effects of these drugs in patients with acute myocardial infarction have been lacking.METHODS: We randomly assigned patients with myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both to receive either sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or ramipril (5 mg twice daily) in addition to recommended therapy. The primary outcome was death from cardiovascular causes or incident heart failure (outpatient symptomatic heart failure or heart failure leading to hospitalization), whichever occurred first.RESULTS: A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 patients (13.2%) in the ramipril group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P=0.17). Death from cardiovascular causes or hospitalization for heart failure occurred in 308 patients (10.9%) in the sacubitril-valsartan group and in 335 patients (11.8%) in the ramipril group (hazard ratio, 0.91; 95% CI, 0.78 to 1.07); death from cardiovascular causes in 168 (5.9%) and 191 (6.7%), respectively (hazard ratio, 0.87; 95% CI, 0.71 to 1.08); and death from any cause in 213 (7.5%) and 242 (8.5%), respectively (hazard ratio, 0.88; 95% CI, 0.73 to 1.05). Treatment was discontinued because of an adverse event in 357 patients (12.6%) in the sacubitril-valsartan group and 379 patients (13.4%) in the ramipril group.CONCLUSIONS: Sacubitril-valsartan was not associated with a significantly lower incidence of death from cardiovascular causes or incident heart failure than ramipril among patients with acute myocardial infarction. (Funded by Novartis; PARADISE-MI ClinicalTrials.gov number, NCT02924727.).

View details for DOI 10.1056/NEJMoa2104508

View details for PubMedID 34758252
Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. Heart failure Minamisawa, M., Claggett, B., Suzuki, K., Hegde, S. M., Shah, A. M., Desai, A. S., Lewis, E. F., Shah, S. J., Sweitzer, N. K., Fang, J. C., Anand, I. S., O'Meara, E., Rouleau, J., Pitt, B., Pfeffer, M. A., Solomon, S. D., Vardeny, O. 2021: CIRCHEARTFAILURE120008293 More

Abstract

BACKGROUND: Polypharmacy is associated with a poor prognosis in the elderly, however, information on the association of polypharmacy with cardiovascular outcomes in heart failure with preserved ejection fraction is sparse. This study sought to investigate the relationship between polypharmacy and adverse cardiovascular events in patients with heart failure with preserved ejection fraction.METHODS: Baseline total number of medications was determined in 1758 patients with heart failure with preserved ejection fraction enrolled in the Americas regions of the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), by 3 categories: nonpolypharmacy (<5 medications), polypharmacy (5-9), and hyper-polypharmacy (≥10). We examined the relationship of polypharmacy status with the primary outcome (cardiovascular death, HF hospitalization, or aborted cardiac arrest), hospitalizations for any reason, and serious adverse events.RESULTS: The proportion of patients taking 5 or more medications was 92.5% (inclusive of polypharmacy [38.7%] and hyper-polypharmacy [53.8%]). Over a 2.9-year median follow-up, compared with patients with polypharmacy, hyper-polypharmacy was associated with an increased risk for the primary outcome, hospitalization for any reason and any serious adverse events in the univariable analysis, but not significantly associated with mortality. After multivariable adjustment for demographic and comorbidities, hyper-polypharmacy remained significantly associated with an increased risk for hospitalization for any reason (hazard ratio, 1.22 [95% CI, 1.05-1.41]; P=0.009) and any serious adverse events (hazard ratio, 1.23 [95% CI, 1.07-1.42]; P=0.005), whereas the primary outcome was no longer statistically significant.CONCLUSIONS: Hyper-polypharmacy was common and associated with an elevated risk of hospitalization for any reason and any serious adverse events in patients with heart failure with preserved ejection fraction. There were no significant associations between polypharmacy status and mortality.

View details for DOI 10.1161/CIRCHEARTFAILURE.120.008293

View details for PubMedID 34674539
Association of Myocardial Blood Flow Reserve With Adverse Left Ventricular Remodeling in Patients With Aortic Stenosis: The Microvascular Disease in Aortic Stenosis (MIDAS) Study. JAMA cardiology Zhou, W., Sun, Y., Divakaran, S., Bajaj, N. S., Gupta, A., Chandra, A., Morgan, V., Barrett, L., Martell, L., Bibbo, C. F., Hainer, J., Lewis, E. F., Taqueti, V. R., Dorbala, S., Blankstein, R., Slomka, P., Shah, P. B., Kaneko, T., Adler, D. S., O'Gara, P., Di Carli, M. F. 2021 More

Abstract

Importance: Impaired myocardial flow reserve (MFR) and stress myocardial blood flow (MBF) on positron emission tomography (PET) myocardial perfusion imaging may identify adverse myocardial characteristics, including myocardial stress and injury in aortic stenosis (AS).Objective: To investigate whether MFR and stress MBF are associated with LV structure and function derangements, and whether these parameters improve after aortic valve replacement (AVR).Design, Setting, and Participants: In this single-center prospective observational study in Boston, Massachusetts, from 2018 to 2020, patients with predominantly moderate to severe AS underwent ammonia N13 PET myocardial perfusion imaging for myocardial blood flow (MBF) quantification, resting transthoracic echocardiography (TTE) for assessment of myocardial structure and function, and measurement of circulating biomarkers for myocardial injury and wall stress. Evaluation of health status and functional capacity was also performed. A subset of patients underwent repeated assessment 6 months after AVR. A control group included patients without AS matched for age, sex, and summed stress score who underwent symptom-prompted ammonia N13 PET and TTE within 90 days.Exposures: MBF and MFR quantified on ammonia N13 PET myocardial perfusion imaging.Main Outcomes and Measures: LV structure and function parameters, including echocardiographic global longitudinal strain (GLS), circulating high-sensitivity troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-pro BNP), health status, and functional capacity.Results: There were 34 patients with AS (1 mild, 9 moderate, and 24 severe) and 34 matched control individuals. MFR was independently associated with GLS and LV ejection fraction, (beta,-0.31; P=.03; beta, 0.41; P=.002, respectively). Stress MBF was associated with hs-cTnT (unadjusted beta, -0.48; P=.005) and log NT-pro BNP (unadjusted beta, -0.37; P=.045). The combination of low stress MBF and high hs-cTnT was associated with higher interventricular septal thickness in diastole, relative wall thickness, and worse GLS compared with high stress MBF and low hs-cTnT (12.4 mm vs 10.0 mm; P=.008; 0.62 vs 0.46; P=.02; and -13.47 vs -17.11; P=.006, respectively). In 9 patients studied 6 months after AVR, mean (SD) MFR improved from 1.73 (0.57) to 2.11 (0.50) (P=.008).Conclusions and Relevance: In this study, in AS, MFR and stress MBF were associated with adverse myocardial characteristics, including markers of myocardial injury and wall stress, suggesting that MFR may be an early sensitive marker for myocardial decompensation.

View details for DOI 10.1001/jamacardio.2021.3396

View details for PubMedID 34524397
A fourth pillar for all in the treatment of heart failure. European heart journal Lewis, E. F. 2021 More

View details for DOI 10.1093/eurheartj/ehab612

View details for PubMedID 34516624
Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. JAMA DeVore, A. D., Granger, B. B., Fonarow, G. C., Al-Khalidi, H. R., Albert, N. M., Lewis, E. F., Butler, J., Pina, I. L., Allen, L. A., Yancy, C. W., Cooper, L. B., Felker, G. M., Kaltenbach, L. A., McRae, A. T., Lanfear, D. E., Harrison, R. W., Disch, M., Ariely, D., Miller, J. M., Granger, C. B., Hernandez, A. F. 2021; 326 (4): 314-323 More

Abstract

Importance: Adoption of guideline-directed medical therapy for patients with heart failure is variable. Interventions to improve guideline-directed medical therapy have failed to consistently achieve target metrics, and limited data exist to inform efforts to improve heart failure quality of care.Objective: To evaluate the effect of a hospital and postdischarge quality improvement intervention compared with usual care on heart failure outcomes and care.Design, Setting, and Participants: This cluster randomized clinical trial was conducted at 161 US hospitals and included 5647 patients (2675 intervention vs 2972 usual care) followed up after a hospital discharge for acute heart failure with reduced ejection fraction (HFrEF). The trial was performed from 2017 to 2020, and the date of final follow-up was August 31, 2020.Interventions: Hospitals (n=82) randomized to a hospital and postdischarge quality improvement intervention received regular education of clinicians by a trained group of heart failure and quality improvement experts and audit and feedback on heart failure process measures (eg, use of guideline-directed medical therapy for HFrEF) and outcomes. Hospitals (n=79) randomized to usual care received access to a generalized heart failure education website.Main Outcomes and Measures: The coprimary outcomes were a composite of first heart failure rehospitalization or all-cause mortality and change in an opportunity-based composite score for heart failure quality (percentage of recommendations followed).Results: Among 5647 patients (mean age, 63 years; 33% women; 38% Black; 87% chronic heart failure; 49% recent heart failure hospitalization), vital status was known for 5636 (99.8%). Heart failure rehospitalization or all-cause mortality occurred in 38.6% in the intervention group vs 39.2% in usual care (adjusted hazard ratio, 0.92 [95% CI, 0.81 to 1.05). The baseline quality-of-care score was 42.1% vs 45.5%, respectively, and the change from baseline to follow-up was 2.3% vs -1.0% (difference, 3.3% [95% CI, -0.8% to 7.3%]), with no significant difference between the 2 groups in the odds of achieving a higher composite quality score at last follow-up (adjusted odds ratio, 1.06 [95% CI, 0.93 to 1.21]).Conclusions and Relevance: Among patients with HFrEF in hospitals randomized to a hospital and postdischarge quality improvement intervention vs usual care, there was no significant difference in time to first heart failure rehospitalization or death, or in change in a composite heart failure quality-of-care score.Trial Registration: ClinicalTrials.gov Identifier: NCT03035474.

View details for DOI 10.1001/jama.2021.8844

View details for PubMedID 34313687

see all 29 publications

BFAM Member Spotlights

Eldrin Lewis, MD, MPH

Abstract

Abstract

Abstract

Abstract